EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tumor microenvironment features of CLDN18.2-positive gastric cancer and advances in targeted and immunotherapy

Yaocan Tan, Yuehong Cui

Medical Oncology · 10.11.2026 · 43 (12)

DOI: 10.1007/s12032-026-03499-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 10.11.2026. Verfasst von Yaocan Tan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Zhongshan Hospital, Fudan University, 200032, Shanghai, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Tumor Microenvironment, Immunotherapy, Claudins. Die Arbeit nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin 18.2 (CLDN18.2) is a tight junction protein expressed predominantly in differentiated epithelial cells of the normal gastric mucosa. Changes in cell polarity and junctional organization during malignant transformation can make its epitopes more accessible to antibodies. The tumor microenvironment of CLDN18.2-positive gastric cancer is heterogeneous. Some cohorts show increased CD8-positive T-cell infiltration alongside stromal remodeling and immunosuppressive signals. Interpretation of immunotherapy outcomes also requires consideration of the programmed death-ligand 1 combined positive score, microsatellite instability, and other molecular and spatial immune features. Zolbetuximab plus chemotherapy improved survival in randomized phase III trials enrolling eligible patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. Evidence for other treatments is at different stages: satri-cel is supported by a randomized phase II trial, while bispecific antibodies and antibody-drug conjugates have also shown antitumor activity in humans. This review relates target distribution, effector cell function, and stromal and metabolic suppression to the mechanisms of these treatment classes. It examines resistance mechanisms, predictive biomarkers, and treatment selection for patients who meet multiple biomarker criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTumor MicroenvironmentImmunotherapyClaudinsAdenocarcinomaHumansMolecular Targeted Therapy

Stichwörter der Autor:innen

CLDN18.2Gastric cancerTargeted therapyTumor microenvironmentZolbetuximab CAR-T

Substanzen

ClaudinsCLDN18 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, 200032, Shanghai, China.
  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, 200032, Shanghai, China. cui.yuehong@zs-hospital.sh.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tan, Y., & Cui, Y. (2026). Tumor microenvironment features of CLDN18.2-positive gastric cancer and advances in targeted and immunotherapy. Medical Oncology, 43(12). https://doi.org/10.1007/s12032-026-03499-w

Vancouver

Tan Y, Cui Y. Tumor microenvironment features of CLDN18.2-positive gastric cancer and advances in targeted and immunotherapy. Medical Oncology. 2026;43(12). doi:10.1007/s12032-026-03499-w

BibTeX
@article{Tan2026,
  author = {Tan, Yaocan and Cui, Yuehong},
  title = {Tumor microenvironment features of CLDN18.2-positive gastric cancer and advances in targeted and immunotherapy},
  journal = {Medical Oncology},
  year = {2026},
  volume = {43},
  number = {12},
  doi = {10.1007/s12032-026-03499-w}
}
Kostenlos starten →